DK1143994T3 - Anvendelse af apoptosis-fremkaldende midler ved fremstilling af et medikament til behandling af (auto)immunitetssygdomme - Google Patents

Anvendelse af apoptosis-fremkaldende midler ved fremstilling af et medikament til behandling af (auto)immunitetssygdomme

Info

Publication number
DK1143994T3
DK1143994T3 DK00900970T DK00900970T DK1143994T3 DK 1143994 T3 DK1143994 T3 DK 1143994T3 DK 00900970 T DK00900970 T DK 00900970T DK 00900970 T DK00900970 T DK 00900970T DK 1143994 T3 DK1143994 T3 DK 1143994T3
Authority
DK
Denmark
Prior art keywords
auto
apoptosis
medicament
manufacture
treatment
Prior art date
Application number
DK00900970T
Other languages
English (en)
Inventor
Mathieu Hubertus Mari Noteborn
Alexandra Maria Pietersen
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd Bv filed Critical Leadd Bv
Application granted granted Critical
Publication of DK1143994T3 publication Critical patent/DK1143994T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK00900970T 1999-01-11 2000-01-10 Anvendelse af apoptosis-fremkaldende midler ved fremstilling af et medikament til behandling af (auto)immunitetssygdomme DK1143994T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200056 1999-01-11
PCT/NL2000/000013 WO2000041497A2 (en) 1999-01-11 2000-01-10 Use of apoptosis inducing agents in the treatment of (auto)immune diseases

Publications (1)

Publication Number Publication Date
DK1143994T3 true DK1143994T3 (da) 2003-10-20

Family

ID=8239795

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00900970T DK1143994T3 (da) 1999-01-11 2000-01-10 Anvendelse af apoptosis-fremkaldende midler ved fremstilling af et medikament til behandling af (auto)immunitetssygdomme

Country Status (18)

Country Link
US (1) US20050271624A1 (da)
EP (1) EP1143994B1 (da)
JP (1) JP2003500336A (da)
AT (1) ATE244014T1 (da)
AU (1) AU3083500A (da)
CA (1) CA2359392A1 (da)
DE (1) DE60003632T2 (da)
DK (1) DK1143994T3 (da)
EA (1) EA200100770A1 (da)
ES (1) ES2202039T3 (da)
HU (1) HUP0200552A2 (da)
IL (2) IL144228A0 (da)
MX (1) MXPA01006998A (da)
NO (1) NO20013397L (da)
PT (1) PT1143994E (da)
TR (1) TR200102713T2 (da)
WO (1) WO2000041497A2 (da)
ZA (1) ZA200105632B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60229924D1 (de) * 2001-03-30 2009-01-02 Leadd Bv Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
DE60217326T2 (de) * 2001-05-25 2007-10-18 Nymox Corp., Saint-Laurent Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
CA2453965C (en) * 2001-07-19 2016-01-19 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5981502A (en) * 1990-09-12 1999-11-09 Leadd B.V. Methods and compositions for inducing apoptosis in tumor cells
EP0878546A1 (en) * 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
ATE241808T1 (de) * 1995-06-07 2003-06-15 Leadd Bv Verwendungen von apoptin
WO1997029201A2 (de) * 1996-02-07 1997-08-14 Max-Delbrück-Centrum für Molekulare Medizin Retroviraler vektor für den gentransfer eines il6-antagonisten in humane hämatopoetische stammzellen
AU729063C (en) * 1997-02-28 2005-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Self-regulated apoptosis of inflammatory cells by gene therapy
JPH10324699A (ja) * 1997-03-21 1998-12-08 Sankyo Co Ltd 抗ヒトＦａｓヒト化抗体
IL123756A0 (en) * 1997-03-21 1998-10-30 Sankyo Co Humanized anti-human FAS antibody

Also Published As

Publication number Publication date
IL144228A0 (en) 2002-05-23
CA2359392A1 (en) 2000-07-20
WO2000041497A2 (en) 2000-07-20
ATE244014T1 (de) 2003-07-15
EA200100770A1 (ru) 2002-02-28
DE60003632T2 (de) 2004-04-15
ES2202039T3 (es) 2004-04-01
JP2003500336A (ja) 2003-01-07
DE60003632D1 (de) 2003-08-07
NO20013397L (no) 2001-09-11
EP1143994B1 (en) 2003-07-02
US20050271624A1 (en) 2005-12-08
EP1143994A2 (en) 2001-10-17
PT1143994E (pt) 2003-11-28
ZA200105632B (en) 2002-10-09
IL144228A (en) 2009-06-15
TR200102713T2 (tr) 2002-05-21
WO2000041497A3 (en) 2000-09-28
HUP0200552A2 (en) 2002-06-29
NO20013397D0 (no) 2001-07-09
MXPA01006998A (es) 2002-05-06
AU3083500A (en) 2000-08-01

Similar Documents

Publication Publication Date Title
TNSN08064A1 (en) Albumin fusion proteins
WO2005077042A3 (en) Albumin fusion proteins
MX2009002816A (es) Proteinas de fusion de albumina.
FI963101A (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
WO2003060071A3 (en) Albumin fusion proteins
WO2001079444A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
AU2002257162A1 (en) Humanized antibodies
WO2002088306A3 (en) Humanized antibodies
CY1108489T1 (el) Παραγωγη τετρασθενων αντισωματων
HUP0300369A2 (hu) Többértékű antitestek és alkalmazásuk
NO20000450L (no) Substituerte fenylalaninforbindelser som inhiberer leukocytt- adhesjon mediert av VLA-4
WO2001064889A3 (en) Tnf-alpha variants for the treatment of tnf-alpha related disorders
MX2009012948A (es) Nuevas indicaciones para la terapia anti-il-1-beta.
DK1143994T3 (da) Anvendelse af apoptosis-fremkaldende midler ved fremstilling af et medikament til behandling af (auto)immunitetssygdomme
DK1220852T3 (da) Substituerede diazepaner
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
MXPA03010728A (es) Moleculas de proteina-2 relacionadas con b7 y uso de las mismas.
EP1475441A3 (fr) Acides nucléiques et polypeptides spécifiques des souches pathogènes du genre Neisseria
DE60038955D1 (de) AN DER OBERFLÄCHE VON KARZINOMZELLEN LOKALISIERTES COLLIGIN/HsP47
DK1377667T3 (da) Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme
WO2006048657A3 (en) Fras related protein
WO2002063013A3 (en) Human acid phosphatase gene
WO2002088345A3 (en) Murine dnasex, medicament containing the same and non-human mammal comprising modified dnasex gene
WO2001030366A3 (de) Verwendung von parvoviren zur verbesserung des allgemeinzustandes bei tumorpatienten oder patienten mit chronischen oder konsumierenden erkrankungen